Bio Job Blog : Bio Jobs : Biotechnology Jobs : Biopharmaceutical Jobs : Bioscience, Biotech Jobs : Bio Job Blog : Biocareer : Bio-Business Training, Biotechnology Training : Jobs in Biology : Internships in Biology : Internships in Biotechnology

There was a very disturbing article on the front page of today’s New York Time about an increasingly popular practice of debarking dogs by people who live in urban areas like New York City. Debarking is accomplished by severing a dog’s vocal cords. The practice may be more widespread than reported because of nuisance pet policies imposed on apartment owners by co-op boards in the city. According to the article, the surgery usually leaves the animal with something between a wheeze and a squeak in lieu of a bark.               

While I am not a card carrying animal rights activist and find excessive barking annoy, I am a dog owner and a biologist who strongly believes in evolution. And, as far as I am concerned, if dogs weren’t meant to bark they wouldn’t! Taking away a dog’s only means of verbal communication (one of my dogs “whines” when she needs to go out and the doggy door is shut) is, in my opinion, detrimental to a dog’s physical and behavioral well being. As one animal behaviorist said in the article:

“Dogs are usually barking because of some frustration. It’s frustrating to be a sheepdog with no sheep. What I’d be concerned about is, if you are debarking a dog and it has an underlying happiness.”

Proponents of the procedure say that it is a harmless procedure and dogs that have been debarked don’t act any differently than they did before the operation. Luckily, many younger veterinarians have deemed that the surgery unnecessary and unethical and refuse to perform it.

My first experience with debarking was after I inadvertently purchased my two dogs from the daughter of a notorious and nefarious New Jersey-based puppy mill breeder. I learned that it is not uncommon among puppy mill owners, to silence their dogs to prevent detection by authorities by shoving metal rebar down their throats. The repeated assaults on a dog’s vocal cords caused scarring and sometimes rupture which, in turn, renders the animal unable to bark. Imagine my outrage when I read that some veterinarians knowingly and willingly perform this surgery because pet owners requested that it be done!

I think the practice of debarking is repugnant, reprehensible and not justified in any circumstances. If your dark has a barking problem, hire an animal behaviorist or call Cesar Milan, aka the Dog Whisperer. It is likely there is an underlying behavioral problem or cause of the problem that can be fixed by behavior modification or pharmacological interventions. Debarking surgery is a convenient and facile solution for pet owners who say they love their dogs but are unwilling to spend the time and effort required to solve the problems. 

In conclusion, if dogs weren’t meant to bark then they would not have when they first appeared on the planet!!!

Until next time...

Good Luck and Don't Forget to Hug Your Puppy Today!!!!

• Email This
• Print
• Comments (4)
• Trackbacks
• Share Link

At long last, marijuana for medical use is legal in New Jersey. As one of his more courageous acts while in office, outgoing Governor John Corzine signed the act into law late yesterday making New Jersey the fourteenth state to legalize medical pot. Four more states and the District of Columbia are expected to follow suit by year's end.

Many things are driving this sea change. The federal government last year announced that it would no longer prosecute medical marijuana smokers in states where it is legal, while the National Institutes of Health has begun funding research on medicinal use in a reversal of a long-standing policy.

Gallup Polls show a solid majority of Americans sympathetic to therapeutic marijuana use.

Unlike California's medical marijuana law which allows the use, possession, and cultivation of marijuana by anyone who possess a "written or oral recommendation" from their physician that he or she "would benefit from medical marijuana," New Jersey's version requires patient identification cards and state-monitored dispensaries -- easing fears that medical use will fuel illegal sales and teenage substance abuse.

While cannabis preparations have been used to relieve nausea and pain since ancient times, research involving medical uses of marijuana was under funded and in many instances discouraged according to an article in today’s New York Times. But over the last 15 years, research on the body's cannabinoid receptors has begun to decipher the chemistry and biology of the positive effects of cannabinoids especially in the areas of glaucoma and chemotherapy induced nausea and vomiting experienced by patients being treated for cancer. More recently, clinical trials have shown that these benefits outweigh the concerns about addiction, heart and respiratory diseases, cancers, and psychoses -- at least, with short-term use.

Marinol, a synthetic cannabinoid pill, is approved by the Food and Drug Administration for treating AIDS-related wasting and chemotherapy-related nausea. But many patients say choking down a slow-acting pill simply doesn't provide the convenient and immediate relief of inhaling marijuana smoke. A new drug, Sativex, made by GW Pharmaceuticals, may renew the debate. A cannabinoid-based oral spray, Sativex is approved in Canada for treating pain in multiple sclerosis and advanced cancer. The company is now completing the clinical testing needed for approval in Europe and the United States.

While I don’t endorse or use illegal drugs (any more), there is no question that medical marijuana helps patients deal with chronic and, in some instances, severely debilitating conditions that impact the overall quality of their lives. I have long contended that just because a substance is deemed illegal it doesn’t negate potential medically-beneficial properties. An example of legal drugs that don’t have any therapeutic benefits and cause much more morbidity and mortality than marijuana are cigarettes and alcohol. Need I say more?

All I gotta say is that we have come a long way since I saw the film Refer Madness while growing up and coming of age in the late 60s. For those of you who haven’t seen the film it is funny whether you are straight or high! object width="445" height="364">

I guess the nation—well NJ anyway—is finally going to pot!

Until next time...

Good Luck and Good Toking (only for medicinal purposes of course)!!!!!!!!!!!

• Email This
• Print
• Comments (2)
• Trackbacks
• Share Link

Johnson & Johnson announced today it would eliminate as many as 8,200 jobs, or 7% of its work force, to help the company cope with what it expects will be a slow economic recovery amid damped demand for drugs, medical devices and consumer products. J&J employs about 117, 000 workers globally. While the job cuts will be global, many losing their jobs will be outside of the US. 

J & J joins a growing list of pharmaceutical and life sciences companies that have announced new layoffs. Pfizer Inc., the world’s biggest drugmaker, plans to fire 19,000 workers following its acquisition of Wyeth and had already cut 10,000 positions since 2007. J&J began firing as many as 4,400 employees from its pharmaceutical and stent divisions in late 2007. Finally, Merck recently announced that it will be eliminating 16,000 workers after its merger with Schering Plough closes later this year.

J&J’s announcement is more bad news for New Jersey which is still reeling from the earlier loss of tens of thousands of pharmaceutical and life sciences jobs.

Until next time...

Good Luck and Good Job Hunting (forget New Jersey)

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

I was sitting around minding my own business (well sort of) and I received the following e-mail message. People must be reading BioJobBlog or something!

In the middle of the worst national job market since the early 1980's, Roche Pharma Research in Nutley, New Jersey is hiring. Specifically, this world class R&D center is seeking to hire 40 scientists to strengthen its research efforts to develop drugs to combat inflammatory diseases like arthritis and asthma.

In addition to Inflammation, Nutley continues to be the headquarters for Roche's Oncology Disease Biology Area, as well as RNA Therapeutics (an emerging area in understanding how genes are turned on and off in cells).

Focusing on drug discovery and non-clinical development, the site has a long tradition of discovering innovative new medicines.

Marcie Geremakis of Roche HR is available to discuss the efforts to recruit the new scientists and why Nutley is an outstanding environment for scientists.  A number of scientists are available to discuss the following:

• Roche's cutting edge scientific approaches to drug discovery focused on meeting the demands of the emerging need for personalized healthcare.

• Roche's intent to provide its scientists with the environment necessary to push forward novel ideas while challenging old paradigms.
• The ability to use state-of-the-art technology and collaborate with Roche's world class scientists across the globe engaged in biomarker discovery, novel biologics platforms, RNAi and diagnostics.

With well over 100 projects in research and more than 60 New Molecular Entities in development, Roche’s pipeline is among the best in the pharmaceuticals industry.

Please call me at 212-468-4306 or e-mail me at jillian.chertok@mslworldwide.com if you would like any additional information, or are interested in scheduling a time to speak with Marcie or one of the scientists at Roche. 

I must disclose that I have no financial arrangement with this agency nor have I ever done business with them before.  But, I figured if there are jobs to be had in this economy I ought to pass them on to folks who are looking.

Until next time...

Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The fourth quarter is over, earnings are being announced and new budgets for the upcoming fiscal year are being evaluated and tweaked. This means that we have officially entered layoff and closure season. Isn’t it great that big companies wait until right before the holiday season to let employees know whether or not they will have a job next year?

That said, two companies, Bristol Myers Squibb (BMS) and Pfizer/Wyeth are the first to kickoff the 2009-2010 season.

BMS announced that it will lay off 25% of its Abilify sales force. This comes only six months after the drugmaker extended its contract with Otsuka Pharmaceutical to market the anti-psychotic and depression drug. Abilify is BMS’s second best selling medication after Plavix that is co-marketed with Sanofi-Aventis. Otsuka developed the drug and BMS markets and distributes it in the US and several European counties.

Abilify loses patent protection in 2012 and faces stiff generic competition in the anti-psychotic and depression markets. A BMS spokesperson declined to say exactly how many reps would be losing their jobs. However, according to a post on the sorely missed and recently resurrected Pharmalot blog there is speculation that Otsuka may hire some of the layed off BMS reps.

In other news, Pfizer/Wyeth announced that it will be closing its facility in Bridgewater, NJ but expanding operations at its Peapack-Gladstone, NJ location. The Bridgewater facility employs 300 people, 100 of which are involved in technology.  The company announced yesterday that it wouldn't be shutting down Wyeth's Collegeville, PA headquarters.

Over 120,000 employees have been laid off by pharma companies in the past three years, many of whom lived and worked in New Jersey.  Unemployment in NJ is hovering around 10%.

Stay tuned for more updates.

Hat tip to Ed at Pharmalot

Until next time...

Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The Philadelphia Inquirer reported today that Pennsylvania state legislators, spearheading efforts to retain jobs in the state after the $68 billion Pfizer-Wyeth merger closes next month, said they were fairly confident many positions would remain at Wyeth's regional operations in Collegeville, Great Valley and other sites. Wyeth employs about 4,500 people in the region - about 3,600 in Collegeville and 900 in Great Valley and elsewhere.

One legislator told the Inquirer that "Representatives of both Pfizer and Wyeth have continued to assure us that we should not worry and they have continued to listen to the case that we have made for as many jobs as possible remaining in Pennsylvania." Pfizer, which plans to cut about 20,000 of the combined companies' 130,000 jobs, would not comment yesterday on the statement or the job situation in Pennsylvania. Gee, what a surprise!

If I were a betting man, I would say that there will be massive layoffs in Pennsylvania and elsewhere after the deal closes. Don’t be surprised if Wyeth’s Madison, NJ headquarters and its research facilities in Princeton NJ are first to get the ax. Finally, I am now firmly convinced that you can never trust a thing that a politician says.

Until next time...

Good Luck and Good Job Hunting!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Emily Rachel Silverstein, a sophomore anthropology major and peace activist at Gettysburg College, was brutally murdered early last Thursday morning, allegedly by her ex-boyfriend, a fellow student and senior at the school. She went to visit him around 3:00 AM to console him because he called her and “he was not acting right” a family friend told me. While I didn’t know Emily well, I knew of her, and by all accounts, her response to her ex-boyfriend’s cry for help was consistent with who she was—a bright, compassionate, peace-loving, social activist who believed that the world could be a better place.   

I attended Emily’s memorial yesterday that was held in Roosevelt, NJ, a town founded by artists and social activists in the late 1940s. My wife, 15 year old son and I were there because Zach is good friends with Jaime, Emily’s younger brother and we know his parents Linda and Bob. Also, one of our best friends’ son dated Emily when she was a senior at Hightstown High School, our local high school. Everybody in the tightly-knit, surrounding communities of East Windsor and Hightstown, NJ has been grieving and affected in some way by Emily’s death.

There were hundreds of people at the memorial, many of whom who spoke and shared their stories about this beautiful and extraordinary young woman. At Gettysburg College she lived at the “Peace House,” founded a new chapter of the resurgent Students for a Democratic Society (SDS for those you who can remember) and was studying Arabic to spend a year abroad in Morocco helping battered women. As one of Emily’s best friends said “she was a vegan, but unlike some vegetarians, she didn’t chide her meat-eating friends because she believed that vegetarianism is a personal choice. That was Emily!” 

Many of the men and boys who spoke sported pony tails and beards and the women and girls who shared childhood and college stories about Emily had flowers in their hair. All of them, regardless of age, race, religion or ethnicity, spoke of Emily’s dreams and plans for peace and social change—the things that mattered most to this vibrant, smart, compassionate young woman who truly believed that she could help change the world by one act of kindness at a time.  

I hadn’t thought much about social activism since the early 1970s and found myself fondly thinking about those days and what they meant to me as young man trying to find his way in the world. And, as more people shared their stories about Emily, I remembered what it felt like to be 19 again and I began to recall my own dreams and plans to make the world a better place. Despite my profound grief and sadness, I began to experience feelings of joy and hope—because unlike some of us who have lost sight of the importance of social activism—many GenYers and Millenials have embraced it, believe in its power and plan to use it to change the world into a safer and more peaceful place.

Emily’s senseless murder was tragic, but the tragedy would be if we don’t try to keep her principles and ideals alive even though she is no longer with us. Please visit a Better World dot net a fund dedicated to the memory of Emily Rachel Silverstein. 

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

Late last week, Roche raised the price of its hostile offer to buy out Genentech to $93 a share, from $86.50. While the Genentech board advised its shareholders that the company is worth $112 per share, many financial analysts believe that the $93 per share offer may entice institutional investors to “pull the trigger” on the deal. Roche also extended its offer to shareholders by a week, until March 20. Roche already owns over 65 percent of Genentech’s outstanding shares.

Roche has indicated that if fewer than half the minority shares were tendered, it would not buy any of the shares tendered by Genentech shareholders. The new offer is likely to bring in more than half the minority shares, which would raise Roche’s ownership to at least 78 percent. About 71 percent of 131 Genentech stockholders who responded to a survey by Deutsche Bank on Friday said they would tender at least some of their shares at $93, and of those, half said they would tender virtually all. It is not clear what will happen if Roche is unable to purchase 100% of Genentech's shares.

Roche is motivated to close the deal as quickly as possible before results are released next month from a clinical trial of Avastin, one of Genentech’s top-selling cancer drugs. That trial, testing Avastin as a treatment for colon cancer after surgical removal of the tumore, could open a huge new market for the drug, which is now approved to treat cancer only at a later stage. Positive results from the trial may push Genentech’s stock price to over $100 per share—something that Roche desperately doesn’t want to happen.

If Roche is successful in its takeover bid, it  will likely to result in massive layoffs at Roche’s Nutley, NJ headquarters. Previously, Roche announced that it would move its US headquarters from Nutley to the Bay area if it acquires Genentech. Not good news for the state of New Jersey which is still reeling from the Pfizer-Wyeth takeover announced six weeks ago and the Merck-Schering Plough merger mentioned earlier today.

Until next time...

Good Luck and Good Job Hunting!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks (1)
• Share Link

Merck announced today that it was buying Schering Plough, the Kenilworth-New Jersey based drug maker, for $41.1 billion. The deal comes only six weeks after Pfizer said that it would purchase NJ-based Wyeth Pharmaceuticals. Superficially, the deal may make sense for the two struggling drug makers—they co-market the cholesterol-lowering drug Vytorin and also have collaborations in the respiratory diseases area. Also, Schering Plough has the European rights to the anti-arthritis drug Remicade and its 2007 purchase of the Dutch biopharmaceutical company Organon Biosciences NV provides access to several potential biotechnology drugs. Nevertheless, the impending merger will ultimately result in job losses and higher unemployment in the state of New Jersey.

Merck currently employs 55,200 workers and Schering-Plough—which grew significantly with its purchase of Organon—also has about 55,000 employees. While no immediate job cuts are planned, a company spokesperson acknowledged that the size of the combined workforce will be reduced by approximately 15%-20% over the next year or so. This means that as many as 20,000 pharmaceutical employees may lose their jobs—a time when unemployment in NJ is approaching 10 percent! My sources tell me that Merck employees are already on edge because of surprise layoffs that occurred in early September, 2008. I suspect that employee anxiety will be extremely high at both companies for the foreseeable future—never a good thing from a productivity point of view.

According to press releases, Schering-Plough's shareholders will get $10.50 in cash and 0.5767 Merck shares for each Schering-Plough share they own. That's a 34 percent premium to Schering-Plough's closing stock price on Friday. Merck's top executive, Chairman and CEO Richard Clark, will lead the combined company, which will attempt to remain a dominant player in treatment areas including cholesterol, respiratory, infectious disease and women's drugs, as well as vaccines. Schering-Plough's CEO, Fred Hassan, will participate in planning integration of the two companies until the close of the deal, which is expected in the fourth quarter. The transaction is to be structured as a reverse merger. Schering-Plough will be the surviving corporation but will take the name Merck. The new company will remain at Merck's headquarters in Whitehouse Station, N.J. and a company spokesperson indicated that a "substantial majority" of employees of Schering-Plough will remain with the newly-formed company. The combined revenue of both companies in 2008 was $47 billion.

Mr. Hassan, a talented, “turn-around” pharmaceutical executive, took over Schering-Plough six years ago as chairman and CEO—a time when the company was struggling with a $500 million fine (the largest ever at the time) imposed by the US Food and Drug Administration because of chronic manufacturing problems. While Schering-Plough is now in much better financial shape than when Mr. Hassan first arrived at the company, its stock price is currently almost identical to the price when he took over (it lost 50% of its value in the past 18 months). Let’s see whether or not Richard Clark, Merck’s current Chairman and CEO, has the mettle to run the combined company. While Schering-Plough has long been rumored to be a takeover target, I don’t think that the Merck-Schering Plough deal is a particularly good or strategic one. Both companies have been struggling of late because of near empty drug pipelines and the ongoing brouhaha over Zetia, Vytorin and Merck’s Vioxx. Further, both companies face price reductions and slumping sales in the next year or so because several blockbuster drugs will lose patent protection and face stiff competition from generic drug manufacturers.

Like the Pfizer-Wyeth deal, the Merck-Schering Plough merger may little more than a red herring. I still fail to see how merging two oversized, struggling pharmaceutical companies can possibly result in the creation of a single successful one. The only upside of the deal is that it allows the newly-formed company to restructure operations, eliminate tens of thousands of jobs and cut costs to bolster its stock share price. That said, I don’t think that an artificially-inflated stock share price necessarily translates into the innovation that historically has been required to create new drugs to treat unmet medical needs!

Until next time...

Good Luck and Good Job Hunting (avoid NJ at all costs)!!!!!!!

• Email This
• Print
• Comments
• Trackbacks (1)
• Share Link

An intrepid reader of BioJobBlog alerted me to a new venture started by Donna Roberts and Dawn Abrams. They allegedly run an operation called Groomers United (based in Shamong, NJ) and advertise on AdoptAPet.com under the same name. The reader cautions “beware of their sob stories and how they are performing a service to the community—they are actually selling older puppy mill breeders at elevated prices claiming that they are “rescuing” these dogs.”  And, for all you cat lovers out there, you can also adopt rescue cats at AdoptAPet. 

I wonder if Groomers United is a registered not-for-profit animal rescue organization. Maybe the State of New Jersey ought to look into it?

• Email This
• Print
• Comments (6)
• Trackbacks
• Share Link

For the past year or so, I have been dealing with Donna Roberts, a so-called dog breeder who recently was convicted in New Jersey on three counts of animal cruelty. Ms Roberts recently contacted me because I chose not to post several of her most recent vitriolic and abusive rants against people who maintain that she is less than scrupulous.

In case you are interested, I didn’t post her most recent comments (like I have in the past) because I am frankly bored with them. That said, when Ms. Roberts has something honest to say, I will gladly publish her comments. I suspect that it will be a cold day in hell before I do that!

If you would like to contact Ms. Roberts directly --to hear what she has to say--please contact her a shadyoakhavs@yahoo.com  I am sure that she would love to  hear from you!

• Email This
• Print
• Comments (4)
• Trackbacks
• Share Link

For those of you who haven’t been able to keep up with the latest pharma layoffs, I came across an article in the Philadelphia Business Journal that does an excellent job of recapping all of the major life sciences layoffs that have taken place in the past year or so. The recent massive pharma layoffs prompted William Ashton, Acting Dean of the University of the Sciences in Philadelphia PA to say “I was in the pharmaceutical industry for 28 years. I’ve never seen such a sea change as is occurring right now. This is really dramatic.” Further, Dr. Ashton predicted that drug companies will increase their use of contract sales forces (CSFs) and contract research organizations (CROs) to contain expenses and that staffing firms will be the winners.

This led to me to wonder what Dean Ashton has been doing for the past 10 years or so because the life sciences industry has already increased its reliance on CROs and CSFs. A quick perusal of the pharma and biotech employees who lost their jobs over the past few years reveals that a majority of them were in sales and R&D. I don’t know whether or not I should break the news to Dean Ashton, but the future is already upon us—another example of how out of touch academia is with industry in the 21^st century.

I think that it is time for industry executives and academicians to begin a serious dialog to determine the type of training that would be appropriate for individuals seeking jobs in the life sciences industry. A failure to do so will likely have a negative adverse effect on the continued growth and future success of the US life science industry.

Until next time…

Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

My recent post about Donna Roberts appears to be a very popular one. No fewer than 50 people have read the post and I am now starting to receive comments from people who have had similar experiences to mine after purchasing puppies from Ms. Roberts and her daughter Grace aka Dawn Abrams. Check out this story and another that I found on the Ripoffreport.com after being alerted about them by one of my readers.

It appears that I am not the only person who received threatening comments from Ms. Roberts. Check out this bogus diatribe against a former customer who dared to question Ms. Roberts’ integrity and veracity after she purchased a very sick puppy from her.

Donna, in case you are wondering (I know you will read this), veracity means “truthfulness”—something that you know nothing about.

Stay tuned for the next installment of the Donna Roberts and Grace Abrams story.

• Email This
• Print
• Comments (3)
• Trackbacks
• Share Link

Let me begin with the good news. The Indianapolis Business journal reported today that Schwarz Pharma Manufacturing, Inc is planning a $12 million expansion of its Seymour, Indiana manufacturing plant and distribution center. When completed the expansion is expected to increase the company's employment in the southern Indiana city from 366 to 516 by 2011. The drug maker-a unit of Schwarz Pharma AG of Monheim, Germany-said it plans to begin hiring managers, business associates and production staff later this month.

And now, the bad news. The Pharmalot Blog reported today that the New Jersey-based generic manufacturer Par Pharmaceuticals is eliminating 26 percent of its workforce expected to save from $45 million to $55 million a year. Jobs will be lost in manufacturing, research and development, and other departments. How much more downsizing and job elimination can New Jersey take before it goes bankrupt? Maybe Icelanders can shed some light on that?

Until next time….

Good Luck and Good Job Hunting

• Email This
• Print
• Comments
• Trackbacks
• Share Link

 I invite those of you who have been following this story to take a few minutes to read the comments that Donna Roberts continues to leave on my blog. Ms Roberts, who was convicted of several counts of animal cruelty in New Jersey last summer, is the mother of Grace aka “Dawn” Abrams who fraudulently sold me my dog Moose several months ago. Although, Ms. Roberts was not involved in the transaction between Grace and me, she continues to send me threatening and bullying e-mail messages proclaiming her daughter’s (and her own) innocence.

I continue to post Ms. Robert’s comments because I want people who read my blog to understand the type of person that I am dealing with! Unfortunately, she reminds me a lot of Sarah Palin—another woman of questionable ethics and integrity. And, I am sad to say that Ms Roberts is about as bright as Ms. Palin too!

Until next time….

Good Luck and Vote for Obama

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

The Pharmalot Blog reported today that Schering Plough will eliminate 1,000sales jobs or 20% of its sales force by October. This latest round of layoffs is part of a reorganization plan that was announced last year to cut 10% of it workforce by 2012 (although must of the downsizing will occur by 2010). The reorganization was announced shortly after Schering purchased Organon Biosciences and the “wheels came off” of its Zetia/Vytorin anti-cholesterol medication franchise.

In other news, BioJobBlog heard through the grapevine that Merck has been quietly laying off workers (since Labor Day) in an attempt to reduce its workforce by 20% over the next few years. Many very talented people who have been with Merck for years are looking for new jobs.

Finally, Montvale, NJ-based Memory Pharmaceuticals announced that it was laying off 55 workers or roughly 50% of its workforce. The company, which went public in a much heralded IPO in 2004, focuses on developing treatments for cognitive disorders. Although the company has never been profitable, the person who ran the company for the past three years (first as president, then CEO and finally CFO) earned $876,807 last year. Not surprisingly, he will be leaving the company as part of the downsizing initiative.

The ongoing pharma slowdown coupled with this week’s Wall Street meltdown (many people who work on Wall Street live in New Jersey) should make New Jersey a very challenging and interesting place to live in the coming months.

Hat tip to Ed at Pharmalot.

Until next time….

Good Luck and Good Job Hunting (I would avoid NJ)!!!!!!

• Email This
• Print
• Comments
• Trackbacks (1)
• Share Link

As the saying goes—the plot thickens. A couple of days ago a person who has been following our unfolding doggy drama recommended that I look into a DNA testing kit for dogs called Wisdom Panel MX. The Wisdom Panel MX was developed by Mars Veterinary, a subsidiary of the candy bar maker that also manufactures and sells dog food.

Scientists at Mars spent about 6 years mining and analyzing canine genome databases and were able to develop breed specific probes that can distinguish between 130 different breeds of dogs with close to 85% reliability. That said, while the test may not be able to reliably tell you exactly what you have, the sensitivity of the test is sufficient to tell you what you don’t have i.e., it will tell you whether or not your dog is a purebred or a mix.

 As I mentioned in previous posts, we were purportedly sold two Havanese dogs. If the dogs are truly Havanese, then the Wisdom Panel should reliably verify that assertion. Similarly, if our dogs are not really Havanese or a mix of Havanese and some other breed (s) then the Wisdom Panel tests ought to be able to tell us that as well.

As luck would have it, on our recent excursion to Maine, we literally ran into two relatively uncommon purebred dogs ( at least uncommon to us) —one was a Maltese and the other a Bichon. Moose—the rescue puppy who was advertised and sold to us as a 9 month-old Havanese—looked almost identical to the Maltese. Further, a so-called groomer (who posted a comment on a previous post about Moose) referred to him a Maltese which tended to validate our idea that Moose was not a Havanese but really a Maltese or a Maltese-mix.  

Again, coincidentally, my wife took Sandy (our Havanese puppy that we previously bought from the same breeder who sold us Moose) to be groomed today. Since it was Sandy’s first visit, the groomer asked what breed she was. After pausing for a second, the groomer replied “I am not  completely sure but I don’t think Sandy is a purebred Havanese –she looks like she has a fair amount of yorkie (Yorkshire terrier) in her.”

The Wisdom Panel MX kits arrived by FedEx today and we are taking the dogs to the vet at 4:00 to have blood drawn. Stay tuned for future updates.

Until next time…

Good Luck and Good Job Hunting!!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

On the heels of yesterday’s announcement that it wants to buy Genentech, Roche, in a surprise move, announced today that it will move its Nutley, NJ-based US corporate headquarters to California. According to a report, research and development activities in oncology and metabolism at the Nutley site will be expanded. However, the company will consolidate all Nutley-based finance and information-technology operations and close manufacturing facilities on the site by 2010. It is not clear how many of Roche’s 3,240 New Jersey employees will be affected by the proposed move to South San Francisco. Suffice it to say, more than a few Roche employees are likely to lose their jobs after the company’s headquarters heads west.

Once dubbed the”nation's medicine chest”, New Jersey has steadily been losing pharmaceutical jobs since 1990 when 20% of all US pharmaceutical jobs were in NJ—at present 13.7% of  American pharmaceutical jobs reside in NJ. It has been a long, slow burn for the pharmaceutical and biotechnology workforce in the Garden State.

The Roche announcement comes as several other New Jersey drug makers, including Schering-Plough and Johnson & Johnson's Ortho Biotech unit, have been laying off workers because of the economic downturn and tough times in the industry. It also comes several days after Barr Pharmaceuticals, headquartered in Montvale, announced that it is being acquired for $7.5 billion by Israeli generics giant Teva.  

The growing scarcity of pharmaceutical and biotechnology jobs coupled with the highest property taxes in the US may cause a mass migration from the state. Not that there is anything wrong with that!!!!!!

Until next time….

Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments (2)
• Trackbacks
• Share Link

Stemcyte, a Taiwan-based company engaged in embryonic stem cell research announced yesterday that it would locate its East Coast operations in NJ. The company already has a research facility in California and is establishing operations in India. Earlier this year, Stemcyte inked a deal with Rutgers University to provide financial support and embryonic stems cells for research conducted by Dr. Wise Young, a long time spinal cord injury researcher and champion of embryonic stem cell research.  New Jersey induced Stemcyte to locate its facility in the Garden State by offering the company $589,000 in business development incentive grants. The new facility is expected to create new jobs and initially employ about 12 people.

This is a small but significant step in New Jersey’s quest to establish itself as leader in embryonic stem cell research. As many of you may know, last fall, New Jersey voters defeated a statewide referendum that would have allowed the State to spend almost $500 million on embryonic stem cell research initiatives. California passed similar legislation several years ago.

The defeat had little to do with the ethics or morality and everything to do with the oppressive property taxes in New Jersey. In case you’re wondering, New Jersey has the highest property taxes in the US!  Many voters simply didn’t want the State to increase its already staggering debt to borrow more money to fund stem cell research (and raise property taxes).

After the announcement, New Jersey Governor Jon Corzine, and former head of the investment firm Goldman Sachs, suggested that he is considering reinstating the referendum for a second vote. However, he noted “not until the economy shows some improvement”.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link